PE Rabbit anti-Human CD353/SLAMF8 Monoclonal Antibody for FC - Q9P0V8

Core Product Specifications and Parameters

Biological Background: CD353/SLAMF8 Function and Localization

• CD353/SLAMF8 (SLAM family member 8) is a single-pass type I membrane protein belonging to the signaling lymphocyte activation molecule (SLAM) family.
• Alternative names include BLAME (B-lymphocyte activator macrophage expressed) and SBBI42; it is also known as BCM-like membrane protein.
• The protein contains an immunoglobulin (Ig) domain and is classified as a glycoprotein with disulfide bonds, reflecting structural features typical of the SLAM family.
• CD353/SLAMF8 is primarily expressed in lymphoid tissues, specifically in lymph node, spleen, thymus, and bone marrow, consistent with a role in immune cell regulation.
• Its function is implicated in B-lineage commitment and/or modulation of B-cell receptor (BCR) signaling, potentially influencing B-cell development and activation.
• The gene undergoes alternative splicing, and the protein is subject to post-translational modifications including glycosylation; it has a calculated molecular weight of approximately 32 kDa (mature form).
• Subcellularly, it localizes to the plasma membrane, as indicated by the presence of a signal peptide and transmembrane helix.
• Keywords from UniProt annotate this protein as a reference proteome member with direct protein sequencing evidence, confirming its expression in human proteomic studies.

Experimental Guidance and Technical Tips

• The immunogen used is a recombinant protein covering amino acids 23-123 (NP_064510.1), which spans the extracellular region; this design targets the ligand-binding domain exposed on the cell surface, making it suitable for flow cytometry applications.
• This antibody is conjugated to PE and validated for flow cytometry (FC); consider titrating the antibody to determine optimal staining concentration for your specific sample and instrument settings.
• Given the tissue expression profile, use appropriate positive controls such as B-cell lines or lymphoid tissue-derived cells (e.g., from bone marrow, spleen, or lymph node) to verify staining patterns.
• As CD353/SLAMF8 may modulate BCR signaling, cross-validate results with functional assays if studying receptor signaling dynamics.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers integrated access to high-quality IVD raw materials, including monoclonal antibodies like this PE-conjugated anti-CD353/SLAMF8 antibody, catering to B-cell research and diagnostic development needs. Our platform provides a reliable supply chain for validated antibody pairs, bulk ancillary reagents, and custom sourcing of rare targets, ensuring smooth progression from concept to clinical application. Partner with CamelBio to streamline your procurement and accelerate your IVD project timelines with comprehensive technical support and consulting services.